Search

Your search keyword '"Fegueux, Nathalie"' showing total 633 results
Start Over Author "Fegueux, Nathalie"
633 results on '"Fegueux, Nathalie"'

51. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: Results from the GET-LALA group

Author

Reman, Oumedaly, Pigneux, Arnaud, Huguet, Françoise, Vey, Norbert, Delannoy, André, Fegueux, Nathalie, de Botton, Stéphane, Stamatoullas, Aspasia, Tournilhac, Olivier, Buzyn, Agnès, Charrin, Christiane, Boucheix, Claude, Gabert, Jean, Lhéritier, Véronique, Vernant, Jean-Paul, Fière, Denis, Dombret, Hervé, and Thomas, Xavier

Published
2008
Full Text
View/download PDF

53. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Yeshurun, Moshe, Labopin, Myriam, Blaise, Didier, Cornelissen, Jan J., Sengeloev, Henrik, Vindelov, Lars, Kuball, Juergen, Chevallier, Patrice, Craddock, Charles, Socie, Gerard, Bilger, Karin, Schouten, Harry C., Fegueux, Nathalie, Goker, Hakan, Maertens, Johan, Bunjes, Donald, Arnold, Renate, Nagler, Arnon, and Mohty, Mohamad

Published
2014
Full Text
View/download PDF

54. Randomized Study of 2 Reduced-Intensity Conditioning Strategies for Human Leukocyte Antigen-Matched, Related Allogeneic Peripheral Blood Stem Cell Transplantation: Prospective Clinical And Socioeconomic Evaluation

Author

Blaise, Didier, Tabrizi, Reza, Boher, Jean-Marie, Le Corroller-Soriano, Anne-Gaëlle, Bay, Jacques-Olivier, Fegueux, Nathalie, Boiron, Jean-Michel, Fürst, Sabine, Castagna, Luca, Chabannon, Christian, Boyer-Chammard, Agnes, Milpied, Noël, Labussière-Wallet, Hélène, Faucher, Catherine, Bardou, Valerie-Jeanne, Mohty, Mohamad, and Michallet, Mauricette

Published
2013
Full Text
View/download PDF

55. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: A GOELAMS study

Author

Guièze, Romain, Cornillet-Lefebvre, Pascale, Lioure, Bruno, Blanchet, Odile, Pigneux, Arnaud, Recher, Christian, Bonmati, Caroline, Fegueux, Nathalie, Bulabois, Claude-Eric, Bouscary, Didier, Vey, Norbert, Delain, Martine, Turlure, Pascal, Himberlin, Chantal, Harousseau, Jean-Luc, Dreyfus, Francois, Béné, Marie C., Ifrah, Norbert, and Chevallier, Patrice

Published
2012
Full Text
View/download PDF

56. Medication non‐adherence after allogeneic hematopoietic cell transplantation in adult and pediatric recipients: a cross sectional study conducted by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

Author

Belaiche, Stephanie, primary, Décaudin, Bertrand, additional, Caron, Alexandre, additional, Depas, Nicolas, additional, Vignaux, Claire, additional, Vigouroux, Stephane, additional, Coiteux, Valérie, additional, Magro, Leonardo, additional, Sirvent, Anne, additional, Huynh, Anne, additional, Turlure, Pascal, additional, Farge, Dominique, additional, Lioure, Bruno, additional, Bruno, Bénédicte, additional, De Berranger, Eva, additional, Maillard, Natacha, additional, Bourhis, Jean‐Henri, additional, Bay, Jacques‐Olivier, additional, Bulabois, Claude‐Eric, additional, Ceballos, Patrice, additional, Fegueux, Nathalie, additional, Hicheri, Yosr, additional, Vincent, Laure, additional, Rialland, Fanny, additional, Gandemer, Virginie, additional, Taque, Sophie, additional, Cornillon, Jérôme, additional, Contentin, Nathalie, additional, Galambrun, Claire, additional, Plantaz, Dominique, additional, Odou, Pascal, additional, and Yakoub‐Agha, Ibrahim, additional

Published
2021
Full Text
View/download PDF

57. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT

Author

Giebel, Sebastian, primary, Labopin, Myriam, additional, Socié, Gerard, additional, Beauvais, David, additional, Klein, Stefan, additional, Wagner-Drouet, Eva Maria, additional, Blaise, Didier, additional, Nguyen-Quoc, Stephanie, additional, Bourhis, Jean Henri, additional, Thiebaut, Anne, additional, Labussière-Wallet, Hélène, additional, Charbonnier, Amandine, additional, Berceanu, Ana, additional, Diez-Martin, José Luis, additional, Fegueux, Nathalie, additional, Esteve, Jordi, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2020
Full Text
View/download PDF

58. Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Giebel, Sebastian, primary, Labopin, Myriam, additional, Houhou, Mohamed, additional, Caillot, Denis, additional, Finke, Jürgen, additional, Blaise, Didier, additional, Fegueux, Nathalie, additional, Ethell, Mark Edward, additional, Cornelissen, Jan J., additional, Forcade, Edouard, additional, Yakoub-Agha, Ibrahim, additional, Lussana, Federico, additional, Maertens, Johan, additional, Bourhis, Jean-Henri, additional, Jindra, Pavel, additional, Gorin, Norbert Claude, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2020
Full Text
View/download PDF

59. A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment

Author

Lamure, Sylvain, primary, Paul, Franciane, additional, Gagez, Anne-Laure, additional, Delage, Jérémy, additional, Vincent, Laure, additional, Fegueux, Nathalie, additional, Sirvent, Anne, additional, Gehlkopf, Eve, additional, Veyrune, Jean Luc, additional, Yang, Lu Zhao, additional, Kanouni, Tarik, additional, Cacheux, Valère, additional, Moreaux, Jérôme, additional, Bonafoux, Beatrice, additional, Cartron, Guillaume, additional, De Vos, John, additional, and Ceballos, Patrice, additional

Published
2020
Full Text
View/download PDF

60. Calcineurin Inhibitor Alone or in Combination with Mycophenolate Mofetil for Graft-Versus-Host-Disease Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Transplantation from Matched Unrelated Donors: A Study from the ALWP of the EBMT

Author

Paviglianiti, Annalisa, primary, Labopin, Myriam, additional, Blaise, Didier, additional, Socié, Gérard, additional, Bulabois, Claude-Eric, additional, Lioure, Bruno, additional, Fegueux, Nathalie, additional, Gerbitz, Arnim, additional, Guillermin, Gaelle, additional, Maertens, Johan, additional, Chevallier, Patrice, additional, Huynh, Anne, additional, Turlure, Pascal, additional, Deconinck, Eric, additional, Forcade, Edouard, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2020
Full Text
View/download PDF

62. Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versustwo induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Author

Nagler, Arnon, Labopin, Myriam, Cornelissen, Jan J., Forcade, Edouard, Chevallier, Patrice, Fegueux, Nathalie, Sierra, Jorge, Desmier, Deborah, Labussière-Wallet, Hélène, Byrne, Jenny L., Loschi, Michael, Blaise, Didier, Baron, Frederic, Ruggeri, Annalisa, and Mohty, Mohamad

Abstract

We compared transplantation outcomes of adult patients with AML that underwent cord blood transplantation (CBT) in CR1 following 1 versus 2 induction courses. Study included 325 patients, 243 (75%) with 1 and 82 (25%) with 2 induction courses. Engraftment was lower for patients achieving CR1 after 1 vs. 2 induction courses: 91% vs. 99% (p= 0.02). Incidence of acute GVHD was similar, 38% and 36% (p= 0.81), as was 2-year chronic GVHD at 23.4% and 27.5%, respectively (p= 0.65). Two-year non-relapse mortality (NRM), relapse incidence (RI), leukemia-free survival (LFS), overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were not statistically different between patients achieving CR1 with 1 vs. 2 induction courses with 23% vs. 24% (p= 0.87), 25% vs. 30% (p= 0.4), 52% vs. 46% (p= 0.3), 59% vs. 50% (p= 0.2), and 44% vs. 41% (p= 0.66), respectively. Results were confirmed by multivariable analysis, NRM (hazard ratio (HR) = 1.1; 95% CI, 0.6–1.8, p= 0.7), RI (HR = 1.4; 95% CI, 0.9–2.3, p= 0.1), LFS (HR = 1.3; 95% CI, 0.9–1.8, p= 0.2), OS (HR = 1.3; 95% CI, 0.9–1.9, p= 0.1), and GRFS (HR = 1.1; 95% CI, 0.8–1.5, p= 0.5). Overall, outcomes of AML patients undergoing CBT in CR1 achieved after 1 or 2 induction courses are similar.

Published
2022
Full Text
View/download PDF

63. Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group

Author

Adès, Lionel, Chevret, Sylvie, Raffoux, Emmanuel, de Botton, Stephane, Guerci, Agnes, Pigneux, Arnaud, Stoppa, Anne Marie, Lamy, Thierry, Rigal-Huguet, Francoise, Vekhoff, Anne, Meyer-Monard, Sandrine, Maloisel, Frederic, Deconinck, Eric, Ferrant, Augustin, Thomas, Xavier, Fegueux, Nathalie, Chomienne, Christine, Dombret, Herve, Degos, Laurent, and Fenaux, Pierre

Published
2006
Full Text
View/download PDF

64. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT

Author

CTI Kuball, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Peric, Zinaida, Labopin, Myriam, Peczynski, Christophe, Polge, Emmanuelle, Cornelissen, Jan, Carpenter, Ben, Potter, Mike, Malladi, Ram, Byrne, Jenny, Schouten, Harry, Fegueux, Nathalie, Socié, Gerard, Rovira, Montserrat, Kuball, Jurgen, Gilleece, Maria, Giebel, Sebastian, Nagler, Arnon, Mohty, Mohamad, CTI Kuball, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Peric, Zinaida, Labopin, Myriam, Peczynski, Christophe, Polge, Emmanuelle, Cornelissen, Jan, Carpenter, Ben, Potter, Mike, Malladi, Ram, Byrne, Jenny, Schouten, Harry, Fegueux, Nathalie, Socié, Gerard, Rovira, Montserrat, Kuball, Jurgen, Gilleece, Maria, Giebel, Sebastian, Nagler, Arnon, and Mohty, Mohamad

Published
2020

65. Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience

Author

Jourdan, Eric, Boiron, Jean-Michel, Dastugue, Nicole, Vey, Norbert, Marit, Gérald, Rigal-Huguet, Françoise, Molina, Lysiane, Fegueux, Nathalie, Pigneux, Arnaud, Recher, Christian, Rossi, Jean-François, Attal, Michel, Sotto, Jean-Jacques, Maraninchi, Dominique, Reiffers, Josy, Bardou, Valerie-Jeanne, Esterni, Benjamin, and Blaise, Didier

Published
2005
Full Text
View/download PDF

68. Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial

Author

Thomas, Xavier, Boiron, Jean-Michel, Huguet, Françoise, Dombret, Hervé, Bradstock, Ken, Vey, Norbert, Kovacsovics, Tibor, Delannoy, André, Fegueux, Nathalie, Fenaux, Pierre, Stamatoullas, Aspasia, Vernant, Jean-Paul, Tournilhac, Olivier, Buzyn, Agnès, Reman, Oumedaly, Charrin, Christiane, Boucheix, Claude, Gabert, Jean, Lhéritier, Véronique, and Fiere, Denis

Published
2004
Full Text
View/download PDF

69. Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials

Author

Boissel, Nicolas, Auclerc, Marie-Françoise, Lhéritier, Véronique, Perel, Yves, Thomas, Xavier, Leblanc, Thierry, Rousselot, Philippe, Cayuela, Jean-Michel, Gabert, Jean, Fegueux, Nathalie, Piguet, Christophe, Huguet-Rigal, Françoise, Berthou, Christian, Boiron, Jean-Michel, Pautas, Cécile, Michel, Gérard, Fière, Denis, Leverger, Guy, Dombret, Hervé, and Baruchel, André

Published
2003

70. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial

Author

de Botton, Stéphane, Chevret, Sylvie, Sanz, Miguel, Dombret, Hervé, Thomas, Xavier, Guerci, Agnès, Fey, Martin, Rayon, Consuelo, Huguet, Françoise, Sotto, Jean-Jacques, Gardin, Claude, Cony Makhoul, Pascale, Travade, Philippe, Solary, Eric, Fegueux, Nathalie, Bordessoule, Dominique, San Miguel, Jesus, Link, Harmut, Desablens, Bernard, Stamatoullas, Aspasia, Deconinck, Eric, Geiser, K, Hess, U, Maloisel, Fréderic, Castaigne, Sylvie, Preudhomme, Claude, Chomienne, Christine, Degos, Laurent, and Fenaux, Pierre

Published
2000

72. Reduced Risk of Relapse for Total Body Irradiation + Fludarabine Compared to Busulphan + Fludarabine As "Reduced-Toxicity" Conditioning for Patients with Acute Myeloid Leukemia Treated with Allohsct in First Complete Remission. a Study By the Acute Leukemia Working Party of the EBMT

Author

Giebel, Sebastian, primary, Labopin, Myriam, primary, Sobczyk Kruszelnicka, Malgorzata Maria, primary, Stelljes, Matthias, primary, Byrne, Jenny, primary, Fegueux, Nathalie, primary, Beelen, Dietrich W., primary, Rovira, Montserrat, primary, Spyridonidis, Alexandros, primary, Blaise, Didier, primary, Bornhäuser, Martin, primary, Karadoğan, Ihsan, primary, Savani, Bipin N., primary, Nagler, Arnon, primary, and Mohty, Mohamad, primary

Published
2019
Full Text
View/download PDF

73. Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. a Study from the ALWP of the EBMT

Author

Paviglianiti, Annalisa, primary, Labopin, Myriam, additional, Blaise, Didier, additional, Socie, Gerard, additional, Bulabois, Claude-Eric, additional, Simand, Celestine, additional, Fegueux, Nathalie, additional, Gerbitz, Armin, additional, Guillerm, Gaëlle, additional, Maertens, Johan, additional, Chevallier, Patrice, additional, Huynh, Anne, additional, Turlure, Pascal, additional, Deconinck, Eric, additional, Forcade, Edouard, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2019
Full Text
View/download PDF

74. Haematopoietic stem cell transplantation in CSF1R-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia

Author

Mochel, Fanny, primary, Delorme, Cécile, additional, Czernecki, Virginie, additional, Froger, Jerome, additional, Cormier, Florence, additional, Ellie, Emmanuel, additional, Fegueux, Nathalie, additional, Lehéricy, Stéphane, additional, Lumbroso, Serge, additional, Schiffmann, Raphael, additional, Aubourg, Patrick, additional, Roze, Emmanuel, additional, Labauge, Pierre, additional, and Nguyen, Stephanie, additional

Published
2019
Full Text
View/download PDF

75. The Role of Donor Selection for a Second Allogeneic Stem Cell Transplantation in Patients with AML Relapsing after a First Transplant; A Study on Behalf of the Acute Leukemia Working Party of EBMT

Author

Shimoni, Avichai, primary, Labopin, Myriam, additional, Finke, Jürgen, additional, Ciceri, Fabio, additional, Deconinck, Eric, additional, Kroger, Nicolaus, additional, Gramatzki, Martin, additional, Stelljes, Matthias, additional, Blaise, Didier, additional, Stölzel, Friedrich, additional, Chevallier, Patrice, additional, Holler, Ernst, additional, Fegueux, Nathalie, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2019
Full Text
View/download PDF

76. Outcome of treatment in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial

Author

Dombret, Hervé, Gabert, Jean, Boiron, Jean-Michel, Rigal-Huguet, Françoise, Blaise, Didier, Thomas, Xavier, Delannoy, André, Buzyn, Agnès, Bilhou-Nabera, Chrystèle, Cayuela, Jean-Michel, Fenaux, Pierre, Bourhis, Jean-Henri, Fegueux, Nathalie, Charrin, Christiane, Boucheix, Claude, Lhéritier, Véronique, Espérou, Hélène, MacIntyre, Elizabeth, Vernant, Jean-Paul, and Fière, Denis

Published
2002
Full Text
View/download PDF

77. Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T‐Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC).

Author

Philippe Walter, Laure, Couronné, Lucile, Jais, Jean‐Philippe, Nguyen, Phong‐Dinh, Blaise, Didier, Pigneux, Arnaud, Socié, Gérard, Thieblemont, Catherine, Bachy, Emmanuel, Fegueux, Nathalie, Chevallier, Patrice, Mohty, Mohamad, Yakoub‐Agha, Ibrahim, Peffault de Latour, Regis, Jaccard, Arnaud, and Hermine, Olivier

Published
2021
Full Text
View/download PDF

78. Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Poire, Xavier, Labopin, Myriam, Polge, Emmanuelle, Passweg, Jakob, Craddock, Charles, Blaise, Didier, Cornelissen, Jan J, Volin, Liisa, Russell, Nigel H, Socié, Gérard, Michallet, Mauricette, Fegueux, Nathalie, Chevallier, Patrice, Brecht, Arne, Hunault-Berger, Mathilde, Mohty, Mohamad, Esteve, Jordi, Nagler, Arnon, UCL - SSS/IREC/SLUC - Pôle St.-Luc, and UCL - (SLuc) Service d'hématologie

Subjects
Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, Gene Duplication, Hematopoietic Stem Cell Transplantation, Humans, Middle Aged, Allografts, Prognosis, Risk Assessment, Survival Analysis, Aged
Abstract

Intermediate-risk cytogenetic acute myeloid leukemia with an internal tandem duplication of (-ITD) is associated with a high risk of relapse, and is now a standard indication for allogeneic stem cell transplantation. Nevertheless, most studies supporting this strategy have been performed in young patients. To address the benefit of allogeneic transplantation in the elderly, we made a selection from the European Society for Blood and Marrow Transplantation registry of intermediate-risk cytogenetic acute myeloid leukemia harboring -ITD in patients aged 60 or over and transplanted from a related or unrelated donor between January 2000 and December 2015. Two hundred and ninety-one patients were identified. Most patients received a reduced-intensity conditioning (82%), while donors consisted of an unrelated donor in 161 (55%) patients. Two hundred and twelve patients received their transplantation in first remission, 37 in second remission and 42 in a more advanced stage of the disease. The 2-year leukemia-free survival rate was 56% in patients in first remission, 22% in those in second remission and 10% in patients with active disease, respectively (

Published
2018

79. A study of 15 cases of primary mediastinal lymphoma of B-cell type

Author

Lavabre-Bertrand, Thierry, Donadio, Daniel, Fegueux, Nathalie, Jessueld, Denis, Taib, Jacques, Charlier, Daniel, Rousset, Therese, Emberger, Jean-Marie, Baldet, Pierre, and Navarro, Maurice

Subjects
Lymphomas -- Development and progression, Thoracic cancer -- Case studies, Non-Hodgkin's lymphomas -- Physiological aspects, Health
Abstract

Fifteen cases of pure supradiapragmatic lymphoma with initial prominent antero-superior mediastinal involvement displaying a B-cell pattern of reactivity were studied. These cases occurred in six men and nine women with a median age of 33 years at diagnosis (range, 23 to 75 years). Supradiapragmatic peripheral lymphadenopathies were present in three cases, and intrathoracic extension to the lung, pericardium, or pleura was possible. In five cases a thymic origin was obvious. All cases exhibited a B-cell pattern of differentiation, with a great variety of histopathologic aspects associated with a high frequency of fibrosis and/or necrosis. Hodgkin's disease was initially misdiagnosed in four cases. The evolution was purely local, with extrathoracic extension in five cases, at the ultimate phase of the disease. The prognosis appeared to be poor with only five patients still alive at a median survival time of 16 months. A complete chemoresistance and radio-resistance was observed in seven cases; only two complete remissions were achieved with aggressive chemotherapy. Prolonged remission could be achieved after surgical reduction of the mass. Primary B-cell mediastinal lymphoma appears to be a distinct clinical entity with local evolution and resistance to therapy. A new therapeutic regimen, which could include surgery in some cases, should be found for this disease. Cancer 1992; 69:2561-2566.

Published
1992

80. The Role of Donor Selection for a Second Allogeneic Stem Cell Transplantation in Patients with AML Relapsing after a First Transplant; A Study on Behalf of the Acute Leukemia Working Party of EBMT

Author

Shimoni, Avichai, primary, Labopin, Myriam, additional, Finke, Jürgen, additional, Ciceri, Fabio, additional, Deconinck, Eric, additional, Kröger, Nicolaus, additional, Gramatzki, Martin, additional, Stelljes, Matthias, additional, Blaise, Didier, additional, Stoelzel, Friedrich, additional, Chevallier, Patrice, additional, Holler, Ernst, additional, Fegueux, Nathalie, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2018
Full Text
View/download PDF

81. Donor Lymphocyte Infusion for Primary Cutaneous T Cell Lymphomas: A Study from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the French Study Group on Cutaneous Lymphomas (GFLEC)

Author

Faiz, Sarah, primary, Abi Rached, Henry, additional, Forcade, Edouard, additional, Milpied, Noel, additional, Beylot-Barry, Marie, additional, Yakoub-Agha, Ibrahim, additional, Fegueux, Nathalie, additional, Dereure, Olivier, additional, Chevallier, Patrice, additional, Huynh, Anne, additional, Rubio, Marie Thérèse, additional, Charbonnier, Amandine, additional, Dulery, Remy, additional, Suarez, Felipe, additional, Granata, Angela, additional, Bay, Jacques-Olivier, additional, Bagot, Martine, additional, Peffault De Latour, Regis, additional, De Masson, Adèle, additional, Carpentier, Olivier, additional, Mortier, Laurent, additional, and Magro, Leonardo, additional

Published
2018
Full Text
View/download PDF

82. Efficacy and Toxicity of Donor Lymphocyte Infusions in the Management of Mixed Donor-Recipient Chimerism Following Allogeneic Stem Cell Transplantation for Lymphoid Malignancies:- a Study of the LWP-EBMT

Author

Robinson, Stephen, primary, Boumendil, Ariane, additional, Khvedelidze, Irma, additional, Finel, Hervé, additional, Peggs, Karl, additional, Malladi, Ram K, additional, Potter, Victoria, additional, Tsoulkani, Anna, additional, Vandenberghe, Elisabeth, additional, Chalandon, Yves, additional, Finke, Jürgen, additional, Marijt, Erik, additional, Furst, Sabine, additional, Schaap, Michel, additional, Hunter, Hannah, additional, Snowden, John A, additional, Wadehra, Karan, additional, Wittnebel, Sebastian, additional, Beelen, Dietrich W., additional, Fegueux, Nathalie, additional, Kroeger, Nicolaus, additional, Dreger, Peter, additional, and Montoto, Silvia, additional

Published
2018
Full Text
View/download PDF

83. Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study

Author

Robinson, Stephen, primary, Boumendil, Ariane, additional, Finel, Hervé, additional, Khvedelidze, Irma, additional, Kanfer, Edward, additional, Peggs, Karl, additional, Furst, Sabine, additional, Ram, Ron, additional, Marijt, Waf, additional, Vandenberghe, Elisabeth, additional, Afanasiev, Boris, additional, Wulf, Gerald, additional, Chalandon, Yves, additional, Maertens, Johan, additional, Tsoulkani, Anna, additional, Schaap, Michel, additional, Beelen, Dietrich W., additional, Gurman, Gunhan, additional, Finke, Jürgen, additional, Wittnebel, Sebastian, additional, Di Bartolomeo, Paolo, additional, Tischer, Johanna, additional, Corradini, Paolo, additional, Caballero, Dolores, additional, Marzolini, Maria A V, additional, Burney, Claire, additional, La Nasa, Giorgio, additional, Potter, Victoria, additional, Bittenbring, Jörg Thomas, additional, Fegueux, Nathalie, additional, Kroeger, Nicolaus, additional, Schmitz, Norbert, additional, Dreger, Peter, additional, and Montoto, Silvia, additional

Published
2018
Full Text
View/download PDF

84. Haploidentical Transplantation Using High Dose Post-Transplant Cyclophosphamide for Patients with Aplastic Anemia : The European Group for Blood and Marrow Transplantation Experience

Author

Prata, Pedro H, primary, Afanasyev, Boris, additional, Eikema, Dirk-Jan, additional, Smiers, Frans, additional, Knol, Cora, additional, Diez-Martin, Jose L., additional, Rocha, Vanderson G., additional, Koc, Yener, additional, Poire, Xavier, additional, Fegueux, Nathalie, additional, Kröger, Nicolaus, additional, Holter, Wolfgang, additional, Bloor, Adrian, additional, Jubert, Charlotte, additional, Al-Seraihy, Amal, additional, Ganser, Arnold, additional, Tilly, Herve, additional, Pioltelli, Pietro, additional, Pérez-Simón, José A., additional, Ho, Aloysius YL, additional, Aljurf, Mahmoud, additional, Russell, Nigel H., additional, Labussière-Wallet, Hélène, additional, Kerre, Tessa, additional, Dufour, Carlo, additional, and Peffault De Latour, Regis, additional

Published
2018
Full Text
View/download PDF

85. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Wo

Author

Czerw, Tomasz, primary, Labopin, Myriam, additional, Giebel, Sebastian, additional, Socié, Gérard, additional, Volin, Liisa, additional, Fegueux, Nathalie, additional, Masszi, Tamás, additional, Blaise, Didier, additional, Chaganti, Sridhar, additional, Cornelissen, Jan J., additional, Passweg, Jakob, additional, Maertens, Johan, additional, Itälä-Remes, Maija, additional, Wu, Depei, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2018
Full Text
View/download PDF

86. Umbilical Cord Blood Transplantation for Secondary AML: A Retrospective Study From the Acute Leukemia Working Party of the Ebmt and Eurocord

Author

Baron, Frédéric, primary, Labopin, Myriam, additional, Ruggeri, Annalisa, additional, Mohty, Mohamad, additional, Blaise, Didier, additional, Chevallier, Patrice, additional, Sanz, Jaime, additional, Fegueux, Nathalie, additional, Cornelissen, Jan, additional, Rambaldi, Alessandro, additional, Savani, Bipin N., additional, Gluckman, Eliane, additional, and Nagler, Arnon, additional

Published
2018
Full Text
View/download PDF

87. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center

Author

Ciurea, Stefan O., primary, Labopin, Myriam, additional, Socie, Gerard, additional, Volin, Liisa, additional, Passweg, Jakob, additional, Chevallier, Patrice, additional, Beelen, Dietrich, additional, Milpied, Noel, additional, Blaise, Didier, additional, Cornelissen, Jan J., additional, Fegueux, Nathalie, additional, Polge, Emmanuelle, additional, Kongtim, Piyanuch, additional, Rondon, Gabriela, additional, Esteve, Jordi, additional, Mohty, Mohamad, additional, Savani, Bipin N., additional, Champlin, Richard E., additional, and Nagler, Arnon, additional

Published
2018
Full Text
View/download PDF

88. Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Poire, Xavier, Labopin, Myriam, Polge, Emmanuelle, Passweg, Jakob, Craddock, Charles, Blaise, Didier, Cornelissen, Jan J, Volin, Liisa, Russell, Nigel H, Socié, Gérard, Michallet, Mauricette, Fegueux, Nathalie, Chevallier, Patrice, Brecht, Arne, Hunault-Berger, Mathilde, Mohty, Mohamad, Esteve, Jordi, Nagler, Arnon, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Poire, Xavier, Labopin, Myriam, Polge, Emmanuelle, Passweg, Jakob, Craddock, Charles, Blaise, Didier, Cornelissen, Jan J, Volin, Liisa, Russell, Nigel H, Socié, Gérard, Michallet, Mauricette, Fegueux, Nathalie, Chevallier, Patrice, Brecht, Arne, Hunault-Berger, Mathilde, Mohty, Mohamad, Esteve, Jordi, and Nagler, Arnon

Abstract

Intermediate-risk cytogenetic acute myeloid leukemia with an internal tandem duplication of (-ITD) is associated with a high risk of relapse, and is now a standard indication for allogeneic stem cell transplantation. Nevertheless, most studies supporting this strategy have been performed in young patients. To address the benefit of allogeneic transplantation in the elderly, we made a selection from the European Society for Blood and Marrow Transplantation registry of intermediate-risk cytogenetic acute myeloid leukemia harboring -ITD in patients aged 60 or over and transplanted from a related or unrelated donor between January 2000 and December 2015. Two hundred and ninety-one patients were identified. Most patients received a reduced-intensity conditioning (82%), while donors consisted of an unrelated donor in 161 (55%) patients. Two hundred and twelve patients received their transplantation in first remission, 37 in second remission and 42 in a more advanced stage of the disease. The 2-year leukemia-free survival rate was 56% in patients in first remission, 22% in those in second remission and 10% in patients with active disease, respectively (<0.005). Non-relapse mortality for the entire cohort was 20%. In multivariate analysis, disease status at transplantation was the most powerful predictor of worse leukemia-free survival, graft--host disease and relapse-free survival, and overall survival. In this elderly population, age was not associated with outcome. Based on the current results, allogeneic transplantation translates into a favorable outcome in fit patients ≥ 60 with -ITD acute myeloid leukemia in first remission, similarly to current treatment recommendations for younger patients.

Published
2018

89. A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

Author

Fenaux, Pierre, Chastang, Claude, Chevret, Sylvie, Sanz, Miguel, Dombret, Hervé, Archimbaud, Eric, Fey, Martin, Rayon, Consuelo, Huguet, Françoise, Sotto, Jean-Jacques, Gardin, Claude, Makhoul, Pascale Cony, Travade, Philippe, Solary, Eric, Fegueux, Nathalie, Bordessoule, Dominique, Miguel, Jesus San, Link, Harmut, Desablens, Bernard, Stamatoullas, Aspasia, Deconinck, E., Maloisel, Fréderic, Castaigne, Sylvie, Preudhomme, Claude, and Degos, Laurent

Published
1999
Full Text
View/download PDF

90. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1gene mutations. A study by the Acute Leukemia Working Party of the EBMT

Author

Giebel, Sebastian, Labopin, Myriam, Socié, Gerard, Beauvais, David, Klein, Stefan, Wagner-Drouet, Eva Maria, Blaise, Didier, Nguyen-Quoc, Stephanie, Bourhis, Jean Henri, Thiebaut, Anne, Labussière-Wallet, Hélène, Charbonnier, Amandine, Berceanu, Ana, Diez-Martin, José Luis, Fegueux, Nathalie, Esteve, Jordi, Nagler, Arnon, and Mohty, Mohamad

Abstract

The presence of IKZF1gene mutations is associated with poor prognosis of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The goal of this retrospective study was to evaluate outcome of allogeneic hematopoietic cell transplantation (allo-HCT) in this population. Ninety-five patients transplanted in first (n= 75) or second (n= 20) complete remission (CR) from either HLA-matched sibling (n= 32), unrelated (n= 47) or haploidentical (n= 16) donor were included in the analysis. The probabilities of the overall survival (OS) and leukemia-free survival (LFS) at 2 years were 55% and 47%, respectively. Relapse incidence (RI) was 32% while non-relapse mortality (NRM), 21%. The incidence of grade II–IV acute graft-versus-host disease (GVHD) and chronic GVHD was 34% and 30%, respectively. The probability of GVHD and relapse-free survival (GRFS) was 35%. In a multivariate analysis positive minimal residual disease (MRD) status was associated with decreased chance of LFS (HR = 3.15, p= 0.004) and OS (HR = 2.37, p= 0.049) as well as increased risk of relapse (HR = 5.87, p= 0.003). Disease stage (CR2 vs. CR1) affected all, LFS, OS, GRFS, RI, and NRM. Results of allo-HCT for patients with BCP-ALL and IKZF1mutations are generally improving, however, individuals with detectable MRD have poor prognosis and require additional intervention prior to transplantation.

Published
2021
Full Text
View/download PDF

91. Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT

Author

Bento, Leyre, Boumendil, Ariane, Finel, Hervé, Khvedelidze, Irma, Blaise, Didier, Fegueux, Nathalie, Castagna, Luca, Forcade, Edouard, Chevallier, Patrice, Mordini, Nicola, Brice, Pauline, Deconinck, Eric, Gramatzki, Martin, Corradini, Paolo, Hunault, Mathilde, Musso, Maurizio, Tsoulkani, Anna, Caballero, Dolores, Nati, Sandro, Montoto, Silvia, and Sureda, Anna

Abstract

Autologous hematopoietic stem cell transplantation (ASCT) is curative for a proportion of patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). However, there is a small group of patients with high-risk of relapse after ASCT that might benefit from other approaches. We conducted a retrospective analysis on 126 patients treated with tandem ASCT-reduced intensity conditioning (RIC)-allogeneic-SCT and reported to the EBMT registry to analyze the efficacy and safety of this approach. Patients were included if they had received an ASCT followed by a planned RIC-SCT in <6 months without relapse between the procedures. The median time between diagnosis and ASCT was 16 months (2–174). The median number of lines prior to ASCT was two (33% of the patients received >3 lines). Forty-one percent were transplanted with active disease. The median follow-up was 44 months (6–130). Three-year-progression-free survival (PFS), overall survival (OS), incidence of relapse (IR), and non-relapse mortality (NRM) after the tandem were 53% (45–64), 73% (65–81), 34% (24–42), and 13% (8–21), respectively. This is the largest series analyzing the efficacy and safety of a tandem approach in R/R HL. The low NRM and IR with promising PFS and OS suggest that this might be an effective procedure for a high-risk population.

Published
2021
Full Text
View/download PDF

92. Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Poiré, Xavier, primary, Labopin, Myriam, additional, Polge, Emmanuelle, additional, Passweg, Jakob, additional, Craddock, Charles, additional, Blaise, Didier, additional, Cornelissen, Jan J., additional, Volin, Liisa, additional, Russell, Nigel H., additional, Socié, Gérard, additional, Michallet, Mauricette, additional, Fegueux, Nathalie, additional, Chevallier, Patrice, additional, Brecht, Arne, additional, Hunault-Berger, Mathilde, additional, Mohty, Mohamad, additional, Esteve, Jordi, additional, and Nagler, Arnon, additional

Published
2017
Full Text
View/download PDF

93. Haploidentical T-Repleted Stem Cell Transplantation (SCT) Has Comparable Survival to 10/10 and 9/10 Unrelated SCT in Poor-Cytogenetics Risk Acute Myeloid Leukemia in First Complete Remission: A Study on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Author

Lorentino, Francesca, primary, Labopin, Myriam, additional, Ciceri, Fabio, additional, Bernardi, Massimo, additional, Esteve, Jordi, additional, Volin, Liisa, additional, Yakoub-Agha, Ibrahim, additional, Craddock, Charles, additional, Passweg, Jakob R., additional, Socie, Gerard, additional, Cornelissen, Jan J, additional, Blaise, Didier, additional, Gedde-Dahl, Tobias, additional, Fegueux, Nathalie, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2017
Full Text
View/download PDF

94. Myeloablative Versus Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in Patients with Prior Myelodysplastic Syndrome/ Myeloproliferative Disorders: An ALWP of EBMT Study

Author

Savani, Bipin N., primary, Boumendil, Ariane, additional, Labopin, Myriam, additional, Finke, Jürgen, additional, Stelljes, Matthias, additional, Ganser, Arnold, additional, Wulf, Gerald, additional, Volin, Liisa, additional, Martin, Sonja, additional, Blaise, Didier, additional, Maertens, Johan, additional, Bourhis, Jean-Henri, additional, Yañez, Lucrecia, additional, Sierra, Jorge, additional, Fegueux, Nathalie, additional, Gehlkopf, Eve, additional, Schroyens, Wilfried, additional, Mailhol, Audrey, additional, Gilleece, Maria Helena, additional, Gorin, Norbert Claude, additional, Esteve, Jordi, additional, Ciceri, Fabio, additional, Baron, Frederic, additional, Schmid, Christoph, additional, Giebel, Sebastian, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2017
Full Text
View/download PDF

95. Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party

Author

Sobh, Mohamad, primary, Michallet, Mauricette, additional, Dubois, Valérie, additional, Iacobelli, Simona, additional, Koster, Linda, additional, Van Biezen, Anja, additional, Fegueux, Nathalie, additional, Tabrizi, Reza, additional, Finke, Jürgen, additional, El-Cheikh, Jean, additional, Schipperus, Martin, additional, Meijer, Ellen, additional, von dem Borne, Peter, additional, Petersen, Eefke, additional, Russell, Nigel, additional, Tholouli, Eleni, additional, Passweg, Jakob, additional, Garban, Frédéric, additional, Maertens, Johan, additional, Chevalier, Patrice, additional, Maillard, Natacha, additional, Volin, Liisa, additional, Francois, Sylvie, additional, Lioure, Bruno, additional, Beguin, Yves, additional, Gluckman, Eliane, additional, Ruggeri, Annalisa, additional, Garderet, Laurent, additional, and Kröger, Nicolaus, additional

Published
2017
Full Text
View/download PDF

96. Outcomes of Allogeneic Hematopoietic Cell Transplantation for AML with Complex Karyotypes: A Retrospective Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and MD Anderson Cancer Center

Author

Ciurea, Stefan O., primary, Labopin, Myriam, additional, Polge, Emmanuelle, additional, Kongtim, Piyanuch, additional, Rondon, Gabriela, additional, Socié, Gerard, additional, Volin, Liisa, additional, Passweg, Jakob, additional, Chevallier, Patrice, additional, Beelen, Dietrich W., additional, Milpied, Noel, additional, Blaise, Didier, additional, Cornelissen, Jan, additional, Fegueux, Nathalie, additional, Mohty, Mohamad, additional, Savani, Bipin N., additional, Champlin, Richard E., additional, and Nagler, Arnon, additional

Published
2017
Full Text
View/download PDF

97. Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT

Author

Canaani, Jonathan, primary, Beohou, Eric, additional, Labopin, Myriam, additional, Socié, Gerard, additional, Huynh, Anne, additional, Volin, Liisa, additional, Cornelissen, Jan, additional, Milpied, Noel, additional, Gedde-Dahl, Tobias, additional, Deconinck, Eric, additional, Fegueux, Nathalie, additional, Blaise, Didier, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2017
Full Text
View/download PDF

98. Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study

Author

Pigneux, Arnaud, primary, Béné, Marie C., additional, Guardiola, Philippe, additional, Recher, Christian, additional, Hamel, Jean-Francois, additional, Sauvezie, Mathieu, additional, Harousseau, Jean-Luc, additional, Tournilhac, Olivier, additional, Witz, Francis, additional, Berthou, Christian, additional, Escoffre-Barbe, Martine, additional, Guyotat, Denis, additional, Fegueux, Nathalie, additional, Himberlin, Chantal, additional, Hunault, Mathilde, additional, Delain, Martine, additional, Lioure, Bruno, additional, Jourdan, Eric, additional, Bauduer, Frederic, additional, Dreyfus, Francois, additional, Cahn, Jean-Yves, additional, Sotto, Jean-Jacques, additional, and Ifrah, Norbert, additional

Published
2017
Full Text
View/download PDF

99. Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor

Author

Deteix, Clémence, Mesnil, Florence, Furst, Sabine, Milpied, Noel, Yakoub-Agha, Ibrahim, Fegueux, Nathalie, Latour, Régis Peffault de, Mohty, Mohamad, Chevallier, Patrice, Labussière Wallet, Hélène, Huynh, Anne, Larosa, Fabrice, Bourhis, Jean-Henri, Cahn, Jean-Yves, Chantepie, Sylvain, Bay, Jacques-Olivier, Audat, Françoise, Foote, Alison, Faucher, Catherine, Marry, Evelyne, and Garban, Frédéric

Abstract

Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy for acute myeloid leukemia. In the absence of an HLA-matched related or unrelated donor (MRD or MUD), the best alternative donor source remains controversial. Umbilical cord blood and haploidentical donors offer a shorter delay from indication to transplantation. This retrospective multicentre study of a French registry compares overall survival in the 18 months following registration in the absence of a MRD between four types of donors. Between 2012 and 2016, 1302 patients were transplanted using MUD (control, n= 803), mismatched MUD (n= 219), umbilical cord blood (n= 153) and haploidentical (n= 127) donors. Multivariate analyses were conducted for overall survival after registration, after transplant, and transplant-related mortality. After adjustment for variables, the type of donor did not influence any of the three end points. Our results confirmed the significant negative impact of longer time between registration and transplant: HR = 1.04 [1.02–1.06] (p< 0.0001). This indicates a positive correlation between better survival and shorter registration-to-transplantation wait time. In the absence of a sibling donor, the alternative stem cell source does not impact early survival in acute myeloid leukemia patients. The minimization of registration-to-transplantation time should be considered when weighing the alternative donor options.

Published
2020
Full Text
View/download PDF

100. Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

UCL - (SLuc) Département de médecine interne et services associés, UCL - (SLuc) Service d'hématologie, UCL - SSS/IREC/SLUC - Pôle St.-Luc, Poiré, Xavier, Labopin, Myriam, Polge, Emmanuelle, Passweg, Jakob, Craddock, Charles, Blaise, Didier, Cornelissen, Jan J., Volin, Liisa, Russell, Nigel H., Socié, Gérard, Michallet, Mauricette, Fegueux, Nathalie, Chevallier, Patrice, Brecht, Arne, Hunault-Berger, Mathilde, Mohty, Mohamad, Esteve, Jordi, Nagler, Arnon, UCL - (SLuc) Département de médecine interne et services associés, UCL - (SLuc) Service d'hématologie, UCL - SSS/IREC/SLUC - Pôle St.-Luc, Poiré, Xavier, Labopin, Myriam, Polge, Emmanuelle, Passweg, Jakob, Craddock, Charles, Blaise, Didier, Cornelissen, Jan J., Volin, Liisa, Russell, Nigel H., Socié, Gérard, Michallet, Mauricette, Fegueux, Nathalie, Chevallier, Patrice, Brecht, Arne, Hunault-Berger, Mathilde, Mohty, Mohamad, Esteve, Jordi, and Nagler, Arnon

Abstract

Intermediate-risk cytogenetic acute myeloid leukemia with an internal tandem duplication of FLT3 (FLT3-ITD) is associated with a high risk of relapse, and is now a standard indication for allogeneic stem cell transplantation. Nevertheless, most studies supporting this strategy have been performed in young patients. To address the benefit of allogeneic transplantation in the elderly, we made a selection from the European Society for Blood and Marrow Transplantation registry of de novo intermediate-risk cytogenetic acute myeloid leukemia harboring FLT3-ITD in patients aged 60 or over and transplanted from a related or unrelated donor between January 2000 and December 2015. Two hundred and ninety-one patients were identified. Most patients received a reduced-intensity conditioning (82%), while donors consisted of an unrelated donor in 161 (55%) patients. Two hundred and twelve patients received their transplantation in first remission, 37 in second remission and 42 in a more advanced stage of the disease. The 2-year leukemia-free survival rate was 56% in patients in first remission, 22% in those in second remission and 10% in patients with active disease, respectively (P<0.005). Non-relapse mortality for the entire cohort was 20%. In multivariate analysis, disease status at transplantation was the most powerful predictor of worse leukemia-free survival, graft-versus-host disease and relapse-free survival, and overall survival. In this elderly population, age was not associated with outcome. Based on the current results, allogeneic transplantation translates into a favorable outcome in fit patients ≥ 60 with FLT3-ITD acute myeloid leukemia in first remission, similarly to current treatment recommendations for younger patients.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results